<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2327">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05130866</url>
  </required_header>
  <id_info>
    <org_study_id>REC-2282-201</org_study_id>
    <nct_id>NCT05130866</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas</brief_title>
  <acronym>POPLAR-NF2</acronym>
  <official_title>A Parallel-group, Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2 Mutated Meningiomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Recursion Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Recursion Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a parallel-group, two-staged, Phase 2/3, randomized, multi-center study to&#xD;
      investigate the efficacy and safety of REC-2282 in patients with progressive NF2 mutated&#xD;
      meningiomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a parallel-group, two-staged, Phase 2/3, randomized, multi-center study to&#xD;
      investigate the efficacy and safety of REC-2282 in patients with progressive NF2 mutated&#xD;
      meningiomas, with either NF2 disease-related meningioma or recurrent sporadic meningiomas&#xD;
      that have NF2 mutations.&#xD;
&#xD;
      Cohort A will provide early data on efficacy and safety of REC-2282 in participants with&#xD;
      progressive NF2 mutated meningiomas, and provide guidance for the dose in the confirmatory&#xD;
      part of the study (Cohort B). The purpose of Cohort B of the study is to assess the efficacy&#xD;
      and safety of REC-2282 compared with placebo in participants with progressive NF2 mutated&#xD;
      meningiomas.&#xD;
&#xD;
      In both cohorts, there will be a screening period of up to 8 weeks, a treatment period, a&#xD;
      4-week safety follow-up period after the end of treatment, and a 6-month post-study&#xD;
      follow-up. The first 8 participants enrolled in Cohort A will complete a food effect run-in&#xD;
      sub study. At the end of the study period, participants may be offered participation in an&#xD;
      open-label extension (OLE) period.&#xD;
&#xD;
      In Cohort A, adult participants will be randomized to one of two dose levels of REC-2282.&#xD;
&#xD;
      In Cohort B, participants will be randomized to REC-2282 treatment (dose to be determined&#xD;
      from Cohort A) arm or placebo arm in a ratio of 2:1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2027</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Parallel-group, Two-staged, Phase 2/3, Randomized, Multicenter Efficacy and Safety Study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Masking applies to Cohort B only.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) in Cohort A</measure>
    <time_frame>6 months</time_frame>
    <description>The proportion of participants in Cohort A who are alive and progression-free after 6 cycles of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS) in Cohort B</measure>
    <time_frame>Time from the date of randomization until disease progression or death from any cause, whichever occurs first, assessed up to 24 months.</time_frame>
    <description>In Cohort B, the time from the date of randomization until disease progression or death from any cause, whichever occurs first.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">89</enrollment>
  <condition>Neurofibromatosis Type 2</condition>
  <arm_group>
    <arm_group_label>Cohort A Adults, Dose 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A Adults, Dose 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A Adolescents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting dose of 30 mg followed by dose escalation to 40 mg and 60 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose TBD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REC-2282</intervention_name>
    <description>Participants will receive REC-2282 3 times per week orally for 3 weeks followed by 1 week off for a 4-week cycle.</description>
    <arm_group_label>Cohort A Adolescents</arm_group_label>
    <arm_group_label>Cohort A Adults, Dose 40 mg</arm_group_label>
    <arm_group_label>Cohort A Adults, Dose 60 mg</arm_group_label>
    <arm_group_label>Cohort B Active</arm_group_label>
    <other_name>AR-42</other_name>
    <other_name>OSU-HDAC42</other_name>
    <other_name>NSC-D736012</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo orally 3 times per week for 3 weeks followed by 1 week off for a 4-week cycle.</description>
    <arm_group_label>Cohort B Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. â‰¥12 years of age and weighing at least 40 kg&#xD;
&#xD;
          2. Progressive meningioma that is amenable to volumetric analysis&#xD;
&#xD;
          3. Has either 1) sporadic meningioma with confirmed NF2 mutation; or, 2) confirmed&#xD;
             diagnosis of NF2 disease (revised Manchester criteria); or, 3) at least one&#xD;
             NF2-related tumor (with pathogenic germline or proven mosaic NF2 variant)&#xD;
&#xD;
          4. Adequate bone marrow function&#xD;
&#xD;
          5. Has provided written informed consent/assent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Progressive disease associated with significant or disabling clinical symptoms likely&#xD;
             to require surgery or radiation therapy within the next 3 months.&#xD;
&#xD;
          2. Received prior surgery, radiosurgery, or laser interstitial thermal therapy in the&#xD;
             target tumor, or immediately adjacent to the target tumor within 6 months prior to&#xD;
             screening.&#xD;
&#xD;
          3. Received an anti- tumor agent for meningioma within 3 months, or 5 half-lives&#xD;
             (whichever is longer), prior to screening.&#xD;
&#xD;
          4. History of an active malignancy within the previous 3 years except for localized&#xD;
             cancers that are considered cured, and, in the opinion of the investigator, present a&#xD;
             low risk of recurrence.&#xD;
&#xD;
          5. Received another investigational drug within 30 days prior to screening&#xD;
&#xD;
          6. Pregnant, lactating, or is planning to attempt to become pregnant or impregnate&#xD;
             someone during this study or within 90 days after the last dose of IMP.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rebecca Rynders, RN, MS</last_name>
    <phone>385-374-1724</phone>
    <email>clinicaltrials@recursionpharma.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 10, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neurofibromatosis Type 2; Neurofibromatosis Type II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningioma</mesh_term>
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Neurofibromatosis 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

